Majority of Medical Marijuana Products Have Mislabeling Issues: Study

Majority of Medical Marijuana Products Have Mislabeling Issues: Study

Nearly two-third of Medical marijuana products suffer from mislabeling, as per a new study published in the Journal of the American Medical Association. While medical marijuana marketers claim positive impact of products for chronic pain, seizures, PTSD and many other ailments, the labeling of products is correct only in 31 percent of the cases evaluated by the study team. Medical marijuana enjoys legal status in 29 states but it is still illegal under federal law. Due to its legal status, the Food and Drug Administration doesn’t regulate derivates of marijuana.

The study was led by Marcel Bonn-Miller, an adjunct assistant professor of psychology in psychiatry at the University of Pennsylvania. The demand for cannabidiol (CBD), a constituent of the cannabis plant, has been increasing over the past few quarters and many companies have started offering derivates of the plant.

Talking about mislabeling of medical marijuana products, Bonn-Miller said, “More and more evidence is coming out that CBD can be helpful for a variety of conditions, from anxiety to inflammation to seizures and epilepsy.”

The study team informed, “Discrepancies between federal and state cannabis laws have resulted in inadequate regulation and oversight, leading to inaccurate labeling of some products.” The study team added that they would request authorities to keep a close check on labeling of medical marijuana products.

Consumers should be knowing what they are buying. Correct labeling is also important to rule out the risk of over-dosage. The study team found that 43 percent of the product samples had more CBD than claimed on the label while 26 percent of the products contained less CBD. Only 32 percent of the products contained the correct amount of CBD (within the acceptable margin of error) as claimed on the product label.

Last week, FDA issued warning letters to four companies selling some medical marijuana products online. The sellers were claiming the products could prevent, diagnose, treat, or cure cancer without providing any evidence for their claims.